Your browser doesn't support javascript.
loading
A Randomized Trial of High vs Standard Power Radiofrequency Ablation for Pulmonary Vein Isolation: SHORT-AF.
Lee, Adam C; Voskoboinik, Alex; Cheung, Christopher C; Yogi, Sarah; Tseng, Zian H; Moss, Joshua D; Dewland, Thomas A; Lee, Byron K; Lee, Randall J; Hsia, Henry H; Marcus, Gregory M; Vedantham, Vasanth; Chieng, David; Kistler, Peter M; Dillon, William; Vittinghoff, Eric; Gerstenfeld, Edward P.
Afiliación
  • Lee AC; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
  • Voskoboinik A; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA; Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia.
  • Cheung CC; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
  • Yogi S; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
  • Tseng ZH; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
  • Moss JD; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
  • Dewland TA; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
  • Lee BK; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
  • Lee RJ; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
  • Hsia HH; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
  • Marcus GM; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
  • Vedantham V; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
  • Chieng D; Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia.
  • Kistler PM; Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia.
  • Dillon W; Department of Radiology, University of California-San Francisco, San Francisco, California, USA.
  • Vittinghoff E; Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California, USA.
  • Gerstenfeld EP; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA. Electronic address: edward.gerstenfeld@ucsf.edu.
JACC Clin Electrophysiol ; 9(7 Pt 2): 1038-1047, 2023 07.
Article en En | MEDLINE | ID: mdl-37495318
BACKGROUND: High-power, short duration (HPSD) radiofrequency ablation (RFA) is a commonly used strategy for pulmonary vein isolation (PVI). OBJECTIVES: This study sought to compare HPSD with standard power, standard duration (SPSD) RFA in patients undergoing PVI. METHODS: Patients with paroxysmal or persistent (<1 year) atrial fibrillation (AF) were randomized to HPSD (50 W) or SPSD (25-30 W) RFA to achieve PVI. Outcomes assessed included time to achieve PVI (primary), left atrial dwell time, total procedure time, first-pass isolation, PV reconnection with adenosine, procedure complications including asymptomatic cerebral emboli (ACE), and freedom from atrial arrhythmias. RESULTS: Sixty patients (median age 66 years; 75% male) with paroxysmal (57%) or persistent (43%) AF were randomized to HPSD (n = 29) or SPSD (n = 31). Median time to achieve PVI was shorter with HPSD vs SPSD (87 minutes vs 126 minutes; P = 0.003), as was left atrial dwell time (157 minutes vs 180 minutes; P = 0.04). There were no differences in first-pass isolation (79% vs 76%; P = 0.65) or PV reconnection with adenosine (12% vs 20%; P = 0.26) between groups. At 12 months, recurrent atrial arrhythmias occurred less in the HPSD group compared with the SPSD group (n = 3 of 29 [10%] vs n = 11 of 31 [35%]; HR: 0.26; P = 0.027). There was a trend toward more ACE with HPSD RFA (40% HPSD vs 17% SPSD; P = 0.053). CONCLUSIONS: In patients undergoing AF ablation, HPSD compared with SPSD RFA results in shorter time to achieve PVI, greater freedom from AF at 12 months, and a trend toward increased ACE.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Venas Pulmonares / Fibrilación Atrial / Ablación por Catéter Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male Idioma: En Revista: JACC Clin Electrophysiol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Venas Pulmonares / Fibrilación Atrial / Ablación por Catéter Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male Idioma: En Revista: JACC Clin Electrophysiol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos